| Literature DB >> 33037255 |
Chi-Chin Sun1,2, Chia-Yi Lee3, Yih-Shiou Hwang2,4, Igaki Michihito5, Kyoko Tagami5, Ching-Hsi Hsiao6,7.
Abstract
We aimed to evaluate the effect of warming eyelids on tear-film stability and quality of life (QoL) in video display terminal (VDT) users. A prospective study was conducted and 45 volunteers with ocular symptoms and tear-film instability associated with VDT use were randomly allocated into the study (n = 22) or control groups (n = 23). Subjects in the study group used eyelid warming steamer (EWS) for 2 weeks and tear fluorescein breakup time (TBUT) after single and 2-week EWS treatment, Schirmer I test, ocular surface staining scores, meibomian gland assessment, severity of dry eye disease (DED) and QoL scores after 2-week EWS treatment were analysed. The TBUT improved after both single and 2-week EWS treatment (P = 0.023 and 0.027, respectively) in the study group. The ocular surface staining scores were significantly decreased only in the study group (P = 0.038). About 60% DED patients in the study group shifted towards non-DED and the pattern of distribution was significantly different compared to baseline (P < 0.001). The QoL scores significantly improved in the study group (P = 0.002) with a negative correlation with TBUT. In conclusion, in VDT users with short TBUT, eyelid warming steamer is effective in improving tear-film stability and QoL.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33037255 PMCID: PMC7547003 DOI: 10.1038/s41598-020-73779-6
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Baseline characteristics and ocular findings of the subjects in each group.
| Study group (n = 22) | Control group (n = 23) | P value | |
|---|---|---|---|
| Age (year, mean ± SD) | 35.6 ± 6.3 | 36.7 ± 9.4 | 0.820 |
| TBUT (sec, mean ± SD) | 3.0 ± 1.1 | 2.6 ± 1.3 | 0.232 |
| 14.0 ± 11.7 | 10.8 ± 9.1 | 0.260 | |
| > 5 mm | 17 (77.2%) | 13 (56.5%) | |
| ≤ 5 mm | 5 (22.7%) | 10 (43.5%) | |
| 1.7 ± 1.7 | 1.8 ± 2.2 | 0.527 | |
| 0–2 | 17 (77.3%) | 18 (72.0%) | |
| 3–6 | 5 (22.7%) | 5 (20.0%) | |
| 7–9 | 0 (0.0%) | 2 (8.0%) | |
| 1.5 ± 0.7 | 1.3 ± 0.5 | 0.434 | |
| Grade 0 | 0 | 1 (4.0%) | |
| Grade 1 | 14 (63.6%) | 16 (52.0%) | |
| Grade 2 | 6 (27.3%) | 8 (36.0%) | |
| Grade 3 | 2 (9.1%) | 0 (0.0%) | |
| 0.6 ± 0.6 | 0.7 ± 0.6 | 0.699 | |
| Grade 0 | 10 (45.5%) | 9 (39.1%) | |
| Grade 1 | 11 (50.0%) | 13 (56.5%) | |
| Grade 2 | 1 (4.5%) | 1 (4.4%) | |
| Grade 3 | 0 (0.0%) | 0 (0.0%) |
SD standard deviation.
Figure 1Change in dry eye parameters at the baseline (black column), after 2-week treatment (white column) in the test group and the control group. (a) The change in TBUT. (b) The change in Schirmer test value. (c) The change in ocular surface staining score. *Indicates the significant difference between the baseline and after 2-week treatment with P < 0.05.
Change in the meibomian gland dropout scores and meibum expressibility scores in the subjects after 2-week treatment.
| Study group (n = 11) | Control group (n = 15) | |||
|---|---|---|---|---|
| Baseline | 2-week treatment | Baseline | 2-week treatment | |
| Grade 0 | 5 (45.5%) | 5 (45.5%) | 7 (46.7%) | 7 (46.7%) |
| Grade 1 | 6 (54.5%) | 6 (54.5%) | 7 (46.7%) | 7 (46.7%) |
| Grade 2 | 0 (0.0%) | 0 (0.0%) | 1 (6.6%) | 1 (6.6%) |
| Grade 3 | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Mean ± SD | 0.6 ± 0.5 | 0.6 ± 0.5 | 0.6 ± 0.6 | 0.6 ± 0.6 |
| 1.000 | 1.000 | |||
| Grade 0 | 0 (0.0%) | 3 (27.3%) | 1 (6.7%) | 0 (0.0%) |
| Grade 1 | 6 (54.5%) | 6 (54.5%) | 9 (60.0%) | 10 (66.7%) |
| Grade 2 | 4 (36.4%) | 2 (19.2%) | 5 (33.3%) | 4 (26.7%) |
| Grade 3 | 1 (9.1%) | 0 (0.0%) | 0 (0.0%) | 1 (6.7%) |
| Mean ± SD | 1.6 ± 0.7 | 0.9 ± 0.7 | 1.3 ± 0.6 | 1.5 ± 0.6 |
| 0.054 | 0.487 | |||
Change in the distribution of diagnostic dry eye disease categories by Japanese dry eye disease criteria.
| Study group (n = 22) | Control group (n = 23) | |||||
|---|---|---|---|---|---|---|
| Baseline | 2-week treatment | Baseline | 2-week treatment | |||
| Definite DED (%) | 5 (22.7%) | 2 (9.1%) | 0.000b | 6 (26.1%) | 4 (17.4%) | 0.058 |
| Probable DED (%) | 17 (77.3%) | 7 (31.8%) | 17 (73.9%) | 14 (60.9%) | ||
| Non-DED (%)a | 0 (0.0%) | 13 (59.1%) | 0 (0.0%) | 5 (21.7%) | ||
aDenote the comparison between the two groups, the baseline distribution between the two groups was identical (P = 0.793) while the study group significantly switched to non-DED status compared to the control group after 2-week treatment (P = 0.038).
bDenote significant differences between baseline and after 2-week treatment in each group (P < 0.05).
Figure 2Correlation between the change in tear fluorescein breakup time and Dry Eye-Related Quality of Life Score. (a) The result in the test group. (b) The result in the control group.